YahooSeptember 21, 2026 at 5:00 PM NYLast Month
Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.¹ “Onco360 is grateful for the
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
